ArticleESMO open2022

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.

M Mark et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.